Pharmaceuticals

60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals released FY2025 9 Months Earnings on November 13, 2025 EST, with actual revenue of USD 1.093 M and EPS of USD -3.4823

60 Degrees Pharmaceuticals released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 528.56 K (forecast USD 150 K), actual EPS USD -0.665 (forecast USD -0.46)

60 Degrees Pharmaceuticals released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 307.87 K (forecast USD 320 K), actual EPS USD -1.2631 (forecast USD -1.24)

60 Degrees Pharmaceuticals released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 564.15K, actual EPS USD -2.7962

60 Degrees Pharmaceuticals released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 256.28K (forecast USD 301K), actual EPS USD -1.5541 (forecast USD -1.315)

60 Degrees Pharmaceuticals released FY2024 Q4 earnings on March 27 (EST), actual revenue 261.44 K USD (forecast 234 K USD), actual EPS -2.2766 USD (forecast -4.01 USD)

60 Degrees Pharmaceuticals released FY2024 annual earnings on March 27 (EST), actual revenue 681.35 K USD (forecast 622.5 K USD), actual EPS -18.5454 USD (forecast -24.345 USD)

60 Degrees Pharmaceuticals released FY2024 9 Months Earnings on November 14 (EST), with actual revenue of USD 409.12K and EPS of USD -23.9469

60 Degrees Pharmaceuticals released FY2024 Q3 earnings on November 14 (EST), actual revenue USD 148.11 K (forecast USD 242 K), actual EPS USD -4.6584 (forecast USD -4.35)

60 Degrees Pharmaceuticals Successfully Regains Compliance with NASDAQ Regulations

60 Degrees Pharmaceuticals Restores Compliance with NASDAQ Listing Requirements

60 Degrees Pharmaceuticals released FY2024 Semi-Annual Earnings on August 14 EST, with actual revenue of USD 261.01 K and EPS of USD -21.4033

60 Degrees Pharmaceuticals released FY2024 Q2 earnings on August 14 (EST), actual revenue USD 125.7 K (forecast USD 211.5 K), actual EPS USD -21.1395 (forecast USD -8.4)

60 Degrees Pharmaceuticals Inc announces Q2 2024 earnings

60 Degrees Pharmaceuticals Inc. Receives FDA Orphan Drug Designation for Tafenoquine

60 Degrees Pharmaceuticals released FY2024 Q1 earnings on May 15 (EST), actual revenue USD 135.31 K (forecast USD 150 K), actual EPS USD 1.8523 (forecast USD -11.4)

60 Degrees Pharmaceuticals reports a 515% increase in net product revenue for the first quarter of 2024

60 Degrees Pharmaceuticals Receives FDA Feedback on Metronidazole - Babesiosis Clinical Trial Protocol

60 Degrees Pharmaceuticals released FY2023 Q4 earnings on April 1 (EST), actual revenue 42.71 K USD (forecast 100 K USD), actual EPS -21.9688 USD (forecast -12.3 USD)

60 Degrees Pharmaceuticals released FY2023 annual earnings on April 1 (EST), actual revenue 253.57 K USD (forecast 250 K USD), actual EPS -60.1142 USD (forecast -53.7 USD)

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

禮來

ROCHE HOLDINGS AG

羅氏(ADR)

阿斯利康

諾華制藥

諾和諾德公司

中外制藥(ADR)

UCB(ADR)

第一三共株式會社(ADR)

大塚制藥(ADR)

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap